detoxifying enzymes, including Rv2581c. These results highlight how PROSPECT can not only immediately reveal, with domain-level resolution, the MOA of new inhibitors, allowing the integration of biological insight into early prioritization, but can also illuminate genetic interactions linked to those mechanisms that could inform synergy predictions for combination therapy.
Gomez et al. (Wed,) studied this question.